the over-pumpers on this board=generally wrong, one drug wonder, no patent protection, over priced drug. Most shorting was a higher levels and remains uncovered. There is a reason for this type of short interest. Plus which of the many prevalent jewish funds would have enough guts to attempt a short squeeze.
You are on ignore but let me tell you something that you already know...you are the world's biggest POS and shmuck is too nice in describing you. Go find a hole and crawl into it.
Sentiment: Strong Buy
While all of that is true, the fact still remains, that if QCOR's proper valuation given those risks involved is a solid 10.00 p/e, and with record sales in 4q, we can safely assume that EPS TTM is ATLEAST $3.00, then the stock should AT A MINIMUM be $30 PPS.
My estimate for next earnings in that EPS is on the VERY low side, given most of us on the board agree it somewhere more like $1.00- $1.21, that puts at a better estimate of $3.15 TTM EPS.
Personally, my math puts us at $1.19 for 4Q '12, which would mean the PPs should be $32.